29 May 2019
Pirbright and ViroVet join forces to develop African swine fever antivirals
Researchers at The Pirbright Institute will partner with the Belgian biotechnology company ViroVet to develop the first antiviral drugs that act against African swine fever (ASF). In the absence of a vaccine, antiviral drugs could provide an alternative control method which would help limit clinical…
Read more